Hacer Uçmak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hacer Uçmak has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Tanıl Kendirli
Department of Pediatric Critical Care, Ankara University School of Medicine, Ankara, Türkiye
14 shared publications - Anar Gurbanov
Department of Pediatric Critical Care Medicine, Ankara University Faculty of Medicine, Ankara, Turkey
10 shared publications - Burak Balaban
Division of Pediatrics, Department of Pediatric Intensive Care, Ankara University Faculty of Medicine, Ankara, Turkey
10 shared publications - Edin Botan
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University School of Medicine, Ankara, Türkiye
10 shared publications - Fevzi Kahveci
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University Faculty of Medicine, Türkiye
10 shared publications - Hasan Özen
Department of Pediatric Intensive Care, Selçuk University Faculty of Medicine, Konya, Turkey
10 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (6) , 495-501
Tigecycline Use in Pediatrics: A Comprehensive Analysis of Clinical, Laboratory, and Microbiological Factors
Objective: This study aimed to evaluate the indications and clinical and microbiological outcomes of tigecycline use in pediatric patients and to analyze the factors associated with treatment success and mortality. Methods:The patients receiving tigecycline antibiotic therapy at a tertiary university hospital over a 12year period were evaluated. Results: During the study period, tigecycline was used in 66 patients. The median age of the patients was 11 years (range: 2 months to 18 years), and 40 (60.6%) were male. While 53% of the patients received empirical treatment, 46.9% received targeted therapy. The majority of patients (81.8%) received tigecycline for “off-label” indications, with bacteremia being the most common “off-label” indication. Microbiological and clinical success rates were 77.1% and 66.7%, respectively. While clinical success did not differ significantly between empiric and targeted therapy groups (P=.22), microbiological success was significantly higher in the targeted therapy group (P=.02). No statistically significant differences were observed between indication types. However, mortality was higher in patients with bacteremia who were treated with tigecycline compared with the non-bacteremic group (P=.007). Tigecycline was combined with other antibiotics in all patients. No serious adverse events requiring discontinuation of tigecycline treatment or dose revision were observed during follow-up. Conclusions: This study suggests that tigecycline, due to its broad spectrum of antibacterial activity, may be an important option in children in combination with other antibiotics in the absence of alternative options or in the absence of response to treatment.
- 21 May 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (6) , 495-501
Open AccessTigecycline Use in Pediatrics: A Comprehensive Analysis of Clinical, Laboratory, and Microbiological Factors
Objective: This study aimed to evaluate the indications and clinical and microbiological outcomes of tigecycline use in pediatric patients and to analyze the factors associated with treatment success and mortality. Methods:The patients receiving tigecycline antibiotic therapy at a tertiary university hospital over a 12year period were evaluated. Results: During the study period, tigecycline was used in 66 patients. The median age of the patients was 11 years (range: 2 months to 18 years), and 40 (60.6%) were male. While 53% of the patients received empirical treatment, 46.9% received targeted therapy. The majority of patients (81.8%) received tigecycline for “off-label” indications, with bacteremia being the most common “off-label” indication. Microbiological and clinical success rates were 77.1% and 66.7%, respectively. While clinical success did not differ significantly between empiric and targeted therapy groups (P=.22), microbiological success was significantly higher in the targeted therapy group (P=.02). No statistically significant differences were observed between indication types. However, mortality was higher in patients with bacteremia who were treated with tigecycline compared with the non-bacteremic group (P=.007). Tigecycline was combined with other antibiotics in all patients. No serious adverse events requiring discontinuation of tigecycline treatment or dose revision were observed during follow-up. Conclusions: This study suggests that tigecycline, due to its broad spectrum of antibacterial activity, may be an important option in children in combination with other antibiotics in the absence of alternative options or in the absence of response to treatment.
- 15 April 2026
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 30 (4) , 551-559
Therapeutic Plasma Exchange in the Pediatric Intensive Care Unit: Analysis of Clinical Outcomes
Introduction: To evaluate the indications, clinical outcomes, and predictors of mortality associated with therapeutic plasma exchange (TPE) in critically ill pediatric patients. Methods: A retrospective study including all critically ill children (1 month–18 years) who underwent TPE in a tertiary 30‐bed PICU between January 2023 and November 2025. Data collected included demographics, ASFA 2023–based indications, extracorporeal therapy use, complications, and mortality. Primary outcome was PICU mortality; secondary outcomes included complications and predictors of death. Results: Eighty‐three patients underwent 242 TPE sessions (median: 3 [IQR 2–4]). The leading indication was sepsis/multiple organ dysfunction syndrome (MODS) (65.1%), followed by neurologic (9.6%) and renal (8.4%) diseases. According to the American Society for Apheresis (ASFA) 2023 guidelines, 81.9% of indications were categorized as Category III. TPE was combined with continuous renal replacement therapy (CRRT) in 19.3% and with extracorporeal membrane oxygenation (ECMO) in 3.6% of patients. Overall mortality was 26.5%, with the highest mortality observed in hematologic and rheumatologic groups (50% each). Higher Pediatric Risk of Mortality (PRISM) scores, higher PELOD‐2 scores, elevated Vasoactive‐Inotropic Scores (VIS), and the need for ECMO were independent predictors of mortality ( p < 0.05). Both CRP and procalcitonin levels decreased significantly following TPE ( p < 0.001), with a more pronounced reduction in survivors. TPE‐related complications occurred in 47%, most commonly hypotension (21.7%), hypocalcemia (9.6%), allergic reactions (9.6%), and circuit clotting (6.0%), with no procedure‐related deaths. Conclusion: TPE is feasible and generally safe in critically ill children. Outcomes are primarily influenced by illness severity—particularly high PRISM scores and ECMO requirement—rather than TPE‐specific factors. Given the predominance of Category III indications, prospective multicenter studies are needed to refine pediatric TPE criteria, optimal timing, and patient selection.
- 15 April 2026
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 30 (4) , 551-559
Therapeutic Plasma Exchange in the Pediatric Intensive Care Unit: Analysis of Clinical Outcomes
Introduction: To evaluate the indications, clinical outcomes, and predictors of mortality associated with therapeutic plasma exchange (TPE) in critically ill pediatric patients. Methods: A retrospective study including all critically ill children (1 month–18 years) who underwent TPE in a tertiary 30‐bed PICU between January 2023 and November 2025. Data collected included demographics, ASFA 2023–based indications, extracorporeal therapy use, complications, and mortality. Primary outcome was PICU mortality; secondary outcomes included complications and predictors of death. Results: Eighty‐three patients underwent 242 TPE sessions (median: 3 [IQR 2–4]). The leading indication was sepsis/multiple organ dysfunction syndrome (MODS) (65.1%), followed by neurologic (9.6%) and renal (8.4%) diseases. According to the American Society for Apheresis (ASFA) 2023 guidelines, 81.9% of indications were categorized as Category III. TPE was combined with continuous renal replacement therapy (CRRT) in 19.3% and with extracorporeal membrane oxygenation (ECMO) in 3.6% of patients. Overall mortality was 26.5%, with the highest mortality observed in hematologic and rheumatologic groups (50% each). Higher Pediatric Risk of Mortality (PRISM) scores, higher PELOD‐2 scores, elevated Vasoactive‐Inotropic Scores (VIS), and the need for ECMO were independent predictors of mortality ( p < 0.05). Both CRP and procalcitonin levels decreased significantly following TPE ( p < 0.001), with a more pronounced reduction in survivors. TPE‐related complications occurred in 47%, most commonly hypotension (21.7%), hypocalcemia (9.6%), allergic reactions (9.6%), and circuit clotting (6.0%), with no procedure‐related deaths. Conclusion: TPE is feasible and generally safe in critically ill children. Outcomes are primarily influenced by illness severity—particularly high PRISM scores and ECMO requirement—rather than TPE‐specific factors. Given the predominance of Category III indications, prospective multicenter studies are needed to refine pediatric TPE criteria, optimal timing, and patient selection.
- 8 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 225-231
Optimizing anticoagulation for CKRT in pediatric ECMO: the effectivity of regional citrate anticoagulation
Background This retrospective, descriptive study, conducted in a single-center PICU from June 2014 to May 2023, aimed to analyze the efficacy of adjunctive regional citrate anticoagulation for continuous kidney replacement therapy (CKRT) circuits during extracorporeal membrane oxygenation (ECMO). Methods Patients were divided into two groups based on their CKRT anticoagulation strategy: those receiving regional citrate anticoagulation in addition to systemic heparin (UFH + RCA group) and those receiving only systemic heparin (UFH group). CKRT circuits were also classified as either UFH + RCA or UFH to analyze outcomes specific to each anticoagulation strategy. CKRT circuit lifespan estimation was calculated by dividing the total CKRT duration by the number of circuits used. Results During the study period, 110 pediatric patients were treated with ECMO at our PICU. During ECMO, 64 (58.2%) of these patients required CKRT. Fluid overload and acute kidney injury were the primary indications for CKRT. While not statistically significant, the median estimate CKRT circuit lifespan was longer in the citrate group [84 (38.4–112.0)] than the heparin group [52 (12.0–408.0)]. Circuit changes due to clotting were significantly higher in the heparin group compared to the citrate group (58.1% vs. 31.7%, p = 0.00). Kaplan–Meier analysis revealed a statistically significant difference in the timing of clotting-related circuit changes, favoring UFH + RCA (p = 0.02). Conclusions To the best of our knowledge, our study represents the first comparison of UFH + RCA and UFH alone for CKRT in pediatric ECMO patients. Our findings suggest that using UFH + RCA might help the circuit last longer by decreasing changes caused by clotting. Prospective studies on this topic are needed. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 8 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 225-231
Optimizing anticoagulation for CKRT in pediatric ECMO: the effectivity of regional citrate anticoagulation
Background This retrospective, descriptive study, conducted in a single-center PICU from June 2014 to May 2023, aimed to analyze the efficacy of adjunctive regional citrate anticoagulation for continuous kidney replacement therapy (CKRT) circuits during extracorporeal membrane oxygenation (ECMO). Methods Patients were divided into two groups based on their CKRT anticoagulation strategy: those receiving regional citrate anticoagulation in addition to systemic heparin (UFH + RCA group) and those receiving only systemic heparin (UFH group). CKRT circuits were also classified as either UFH + RCA or UFH to analyze outcomes specific to each anticoagulation strategy. CKRT circuit lifespan estimation was calculated by dividing the total CKRT duration by the number of circuits used. Results During the study period, 110 pediatric patients were treated with ECMO at our PICU. During ECMO, 64 (58.2%) of these patients required CKRT. Fluid overload and acute kidney injury were the primary indications for CKRT. While not statistically significant, the median estimate CKRT circuit lifespan was longer in the citrate group [84 (38.4–112.0)] than the heparin group [52 (12.0–408.0)]. Circuit changes due to clotting were significantly higher in the heparin group compared to the citrate group (58.1% vs. 31.7%, p = 0.00). Kaplan–Meier analysis revealed a statistically significant difference in the timing of clotting-related circuit changes, favoring UFH + RCA (p = 0.02). Conclusions To the best of our knowledge, our study represents the first comparison of UFH + RCA and UFH alone for CKRT in pediatric ECMO patients. Our findings suggest that using UFH + RCA might help the circuit last longer by decreasing changes caused by clotting. Prospective studies on this topic are needed. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 21 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104194
Rotational thromboelastometry (ROTEM) in pediatric intensive care: A single center experience
- 21 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104194
Rotational thromboelastometry (ROTEM) in pediatric intensive care: A single center experience
- Open Access
- 1 January 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (1) , 109-112
Development of anaphylaxis during biopsy of cardiac, hepatic, and subcutaneous hydatid cysts
This case report presents a rare occurrence of both subcutaneous and cardiac hydatid cysts in a pediatric patient. A 10-year-old girl admitted with a rapidly enlarging, painful mass in the right dorsal scapular region. During a biopsy procedure under sedation, the patient developed an anaphylactic reaction and subsequent cardiopulmonary arrest. After successful resuscitation, cardiac echocardiography revealed a large hydatid cyst in the interventricular septum. In conclusion, potential complications should always be considered during invasive procedures. In addition, in patients with musculoskeletal masses, a whole-body magnetic resonance imaging may detect and prevent potential complications at an early stage.
- 1 January 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (1) , 109-112
Open AccessDevelopment of anaphylaxis during biopsy of cardiac, hepatic, and subcutaneous hydatid cysts
This case report presents a rare occurrence of both subcutaneous and cardiac hydatid cysts in a pediatric patient. A 10-year-old girl admitted with a rapidly enlarging, painful mass in the right dorsal scapular region. During a biopsy procedure under sedation, the patient developed an anaphylactic reaction and subsequent cardiopulmonary arrest. After successful resuscitation, cardiac echocardiography revealed a large hydatid cyst in the interventricular septum. In conclusion, potential complications should always be considered during invasive procedures. In addition, in patients with musculoskeletal masses, a whole-body magnetic resonance imaging may detect and prevent potential complications at an early stage.
- 29 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Clinical Cardiovascular Perfusion
- Vol. 1 (3) , 111-114
Successful Extracorporeal Cardiopulmonary Resuscitation in a Case of Severe Tracheal Stenosis after Congenital Heart Surgery
- 29 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Clinical Cardiovascular Perfusion
- Vol. 1 (3) , 111-114
Successful Extracorporeal Cardiopulmonary Resuscitation in a Case of Severe Tracheal Stenosis after Congenital Heart Surgery
- Open Access
- 31 October 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (6) , 600-606
Venovenous Versus Venoarterial Extracorporeal Membrane Oxygenation: Pediatric Acute Respiratory Distress Syndrome
Objective: This study aimed to compare the efficacy, complication, and mortality of patients who were supported by venovenous (VV) extracorporeal membrane oxygenation (ECMO) and venoarterial (VA) ECMO for pediatric acute respiratory distress syndrome (PARDS). Materials and Methods: This study is a single-center, retrospective cohort study between 2014 and 2022. We evaluated to indication of ECMO support, ECMO type, patients’ demographic features, complications, and children's outcomes supported by ECMO for PARDS. Results: Twenty-two patients with PARDS, 12 (54%) with VV, and 10 (46%) with VA ECMO were selected. The median number of days to be intubated before ECMO cannulation was 5 (0-16) days. The distribution of intubated days before the patients underwent ECMO was as follows: 0-1 days, 7 (31.8%) patients; 2-3 days, 2 (9.1%) patients; 4-7 days, 7 (31.8%) patients; 8-14 days, 5 (22.8%) patients; >14 days, 1 (4.5%) patient. The median ECMO cannulation day after admission to the pediatric intensive care unit was 3 (range, 1-9) days in the VV ECMO patient group, whereas it was 8 (range, 0-19) days in the VA ECMO group (P = .02). Considering hospital survival, 4 (45%) patients who underwent double-lumen VV ECMO, 1 (33%) patient who underwent VV ECMO, and 3 (30%) patients who supported by VAECMO survived. There was no difference between the groups in terms of hospital discharge rates. Conclusion: The highest survival rate was found in the VV ECMO patient group established with double-lumen cannulas, similar to the literature. There was no difference in mortality between the groups whose intubation time before ECMO was 14 days or less. Cite this article as: Kahveci F, Karaçoban G, Çelik NA, et al. Venovenous versus venoarterial extracorporeal membrane oxygenation: Pediatric acute respiratory distress syndrome. Turk Arch Pediatr. 2023;58(6):600-606.
- 31 October 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (6) , 600-606
Open AccessVenovenous Versus Venoarterial Extracorporeal Membrane Oxygenation: Pediatric Acute Respiratory Distress Syndrome
Objective: This study aimed to compare the efficacy, complication, and mortality of patients who were supported by venovenous (VV) extracorporeal membrane oxygenation (ECMO) and venoarterial (VA) ECMO for pediatric acute respiratory distress syndrome (PARDS). Materials and Methods: This study is a single-center, retrospective cohort study between 2014 and 2022. We evaluated to indication of ECMO support, ECMO type, patients’ demographic features, complications, and children's outcomes supported by ECMO for PARDS. Results: Twenty-two patients with PARDS, 12 (54%) with VV, and 10 (46%) with VA ECMO were selected. The median number of days to be intubated before ECMO cannulation was 5 (0-16) days. The distribution of intubated days before the patients underwent ECMO was as follows: 0-1 days, 7 (31.8%) patients; 2-3 days, 2 (9.1%) patients; 4-7 days, 7 (31.8%) patients; 8-14 days, 5 (22.8%) patients; >14 days, 1 (4.5%) patient. The median ECMO cannulation day after admission to the pediatric intensive care unit was 3 (range, 1-9) days in the VV ECMO patient group, whereas it was 8 (range, 0-19) days in the VA ECMO group (P = .02). Considering hospital survival, 4 (45%) patients who underwent double-lumen VV ECMO, 1 (33%) patient who underwent VV ECMO, and 3 (30%) patients who supported by VAECMO survived. There was no difference between the groups in terms of hospital discharge rates. Conclusion: The highest survival rate was found in the VV ECMO patient group established with double-lumen cannulas, similar to the literature. There was no difference in mortality between the groups whose intubation time before ECMO was 14 days or less. Cite this article as: Kahveci F, Karaçoban G, Çelik NA, et al. Venovenous versus venoarterial extracorporeal membrane oxygenation: Pediatric acute respiratory distress syndrome. Turk Arch Pediatr. 2023;58(6):600-606.
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 198-204
Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 198-204
Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
- Open Access
- 31 August 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (3) , 371-379
Impact of the COVID-19 pandemic on diabetic ketoacidosis management in the pediatric intensive care unit
Background: Diabetic ketoacidosis (DKA) is a common endocrine emergency in pediatric patients. Early presentation to health facilities, diagnosis, and good management in the pediatric intensive care unit (PICU) are crucial for better outcomes in children with DKA. Methods: This was a single-center, retrospective cohort study conducted between February 2015 and January 2022. Patients with DKA were divided into two groups according to pandemic status and diabetes diagnosis. Both groups were examined in two subcategories (pandemic status: pre-pandemic vs. pandemic; and diabetes diagnosis status: previously diagnosed vs. newly diagnosed).Results: The study enrolled 59 patients, and their mean age was 11±5 years. Forty (68%) had newly diagnosed type 1 diabetes mellitus (T1DM), and 61% received follow-up in the pre-pandemic period. Blood glucose, blood ketone, potassium, phosphorus, creatinine, and alanine transaminase levels were significantly higher in the new-onset T1DM group compared with the previously diagnosed group (P=0.01, P=0.02, P=0.01, P=0.039, and p=0.001, respectively). In patients with newly diagnosed T1DM, length of PICU stays were longer than in those with previously diagnosed T1DM (28.5±8.9 vs. 17.3±6.7 hours, p<0.005). The pandemic group was compared with pre-pandemic group, there was a statistically significant difference in laboratory parameters of pH, HCO3, and lactate and also Pediatric Risk Of Mortality (PRISM) III score. All patients survived, and there were no neurologic sequelae. Conclusion: Patients admitted during the pandemic period were admitted with more severe DKA and had higher PRISM III scores. During the pandemic period, there was an increase in the incidence of DKA in the participating center compared to that before the pandemic. Although the reason for this is not fully known, it could be public health presentations were not effective during the coronavirus disease 2019 (COVID-19) period.
- 31 August 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (3) , 371-379
Open AccessImpact of the COVID-19 pandemic on diabetic ketoacidosis management in the pediatric intensive care unit
Background: Diabetic ketoacidosis (DKA) is a common endocrine emergency in pediatric patients. Early presentation to health facilities, diagnosis, and good management in the pediatric intensive care unit (PICU) are crucial for better outcomes in children with DKA. Methods: This was a single-center, retrospective cohort study conducted between February 2015 and January 2022. Patients with DKA were divided into two groups according to pandemic status and diabetes diagnosis. Both groups were examined in two subcategories (pandemic status: pre-pandemic vs. pandemic; and diabetes diagnosis status: previously diagnosed vs. newly diagnosed).Results: The study enrolled 59 patients, and their mean age was 11±5 years. Forty (68%) had newly diagnosed type 1 diabetes mellitus (T1DM), and 61% received follow-up in the pre-pandemic period. Blood glucose, blood ketone, potassium, phosphorus, creatinine, and alanine transaminase levels were significantly higher in the new-onset T1DM group compared with the previously diagnosed group (P=0.01, P=0.02, P=0.01, P=0.039, and p=0.001, respectively). In patients with newly diagnosed T1DM, length of PICU stays were longer than in those with previously diagnosed T1DM (28.5±8.9 vs. 17.3±6.7 hours, p<0.005). The pandemic group was compared with pre-pandemic group, there was a statistically significant difference in laboratory parameters of pH, HCO3, and lactate and also Pediatric Risk Of Mortality (PRISM) III score. All patients survived, and there were no neurologic sequelae. Conclusion: Patients admitted during the pandemic period were admitted with more severe DKA and had higher PRISM III scores. During the pandemic period, there was an increase in the incidence of DKA in the participating center compared to that before the pandemic. Although the reason for this is not fully known, it could be public health presentations were not effective during the coronavirus disease 2019 (COVID-19) period.